Hypoxic liver injury and cholestasis in critically ill patients

Current Opinion in Critical Care

Volumn 19, Issue 2, 2013, Pages 128-132

  Horvatits, Thomas ^a   Trauner, Michael ^a   Fuhrmann, Valentin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

cholestasis; hypoxic liver injury; intensive care unit; jaundice

Indexed keywords

CARDIOGENIC SHOCK; CHOLESTASIS; CLINICAL FEATURE; CRITICALLY ILL PATIENT; HEPATITIS; HUMAN; HYPOXIC LIVER INJURY; INTENSIVE CARE UNIT; ISCHEMIC HEPATITIS; JAUNDICE; LIVER DYSFUNCTION; LIVER INJURY; LIVER SHOCK; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; OXYGEN SUPPLY; PATHOPHYSIOLOGY; PHYSICIAN; PREVALENCE; PROGNOSIS; REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK;

CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CHOLESTASIS; CRITICAL ILLNESS; DOBUTAMINE; EARLY DIAGNOSIS; FEMALE; FLUID THERAPY; HUMANS; INTENSIVE CARE UNITS; LIVER DISEASES; MALE; MULTIPLE ORGAN FAILURE; PROGNOSIS;

EID: 84874767067     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32835ec9e6     Document Type: Review

References (46)

1. Kramer L, Jordan B, Druml W, et al. Incidence and prognosis of early hepatic dysfunction in critically ill patients-a prospective multicenter study. Crit Care Med 2007; 35:1099-1104. (Pubitemid 46598961)
2. Mesotten D, Wauters J, Van den Berghe G, et al. The effect of strict blood glucose control on biliary sludge and cholestasis in critically ill patients. J Clin Endocrinol Metab 2009; 94:2345-2352.
3. Fuhrmann V, Kneidinger N, Herkner H, et al. Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive CareMed 2011; 37:1302-1310.
4. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710. (Pubitemid 26254283)
5. Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652.
6. Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology 2007; 45:230-241. (Pubitemid 46144383)
7. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JG. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut 1999; 45:129-133. (Pubitemid 29301857)
8. Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine 2003; 82:392-406. (Pubitemid 37448566)
9. Raurich JM, Perez O, Llompart-Pou JA, et al. Incidence and outcome of ischemic hepatitis complicating septic shock. Hepatol Res 2009; 39:700-705.
10. Fuhrmann V, Kneidinger N, Herkner H, et al. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 2009; 35:1397-1405.
11. Sherlock S. Overview of chronic cholestatic conditions in adults: terminology and definitions. Clin Liver Dis 1998; 2:217-233.
12. Jä ger B, Drolz A, Michl B, et al. Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis. Hepatology 2012; 56:2297-2304.
13. Moseley RH. Sepsis and cholestasis. Clin Liver Dis 2004; 8:83-94. (Pubitemid 38373671)
14. Vanwijngaerden YM, Wauters J, Langouche L, et al. Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology 2011; 54:1741-1752.
15. Recknagel P, Gonnert FA, Westermann M, et al. Liver dysfunction and phosphatidylinositol-3-kinase signaling in early sepsis: experimental models in rodent models of peritonitis. PLoS Med 2012; 9:e1001338.
16. Fuhrmann V, Jager B, Zubkova A, Drolz A. Hypoxic hepatitis-epidemiology, pathophysiology and clinical management. Wien Klin Wochensch 2010; 122:129-139.
17. Henrion J, Minette P, Colin L, et al. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. Hepatology 1999; 29:427-433. (Pubitemid 29088446)
18. Ebert EC. Hypoxic liver injury. Mayo Clin ProcV 81 2006; 1232-1236. (Pubitemid 44316289)
19. Fuhrmann V, Madl C, Mueller C, et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology 2006; 131:69-75. (Pubitemid 44015748)
20. Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 2007; 46:1063-1070. (Pubitemid 47354460)
21. Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 2009; 89:1269-1339.
22. Scholtholt J, Shiraishi T. Effect of generalized hypoxia, hypocapnia and hypercapnia on blood flow in the liver and splanchnic region of the anesthetized dog. Pflugers Arch 1970; 318:185-201.
23. Lautt WW. Regulatory processes interacting to maintain hepatic blood flow constancy: vascular compliance, hepatic arterial buffer response, hepatorenal reflex, liver regeneration, escape from vasoconstriction. Hepatol Res 2007; 37:891-903. (Pubitemid 47399917)
24. Amitrano L, Guardascione MA, Martino R, et al. Hypoxic hepatitis occurring in cirrhosis after variceal bleeding: still a lethal disease. J Clin Gastroenterol 2012; 46:608-612.
25. Trauner M, Boyer JL. Cholestatic syndromes. Curr Opin Gastroenterol 2004; 20:220-230. (Pubitemid 38526772)
26. Brienza N, Dalfino L, Cinnella G, et al. Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med 2006; 32:267-274. (Pubitemid 43251148)
27. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365:506-517.
28. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology 2011; 53:1377-1387.
29. Te Boekhorst T, Urlus M, Doesburg W, et al. Etiologic factors of jaundice in severely ill patients. A retrospective study in patients admitted to an intensive care unit with severe trauma or with septic intra-abdominal complications following surgery and without evidence of bile duct obstruction. J Hepatol 1988; 7:111-117.
30. Ruemmele P, Hofstaedter F, Gelbmann CM. Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol 2009; 6:287-295.
31. El Banayosy A, Kizner L, Schueler V, et al. First use of the molecular adsorbent recirculating system technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 2004; 50:332-337. (Pubitemid 38917880)
32. Zittermann A, Engel M, Hohnemann S, et al. Molecular adsorbent recirculating system technique for liver failure due to cardiogenic shock. Thorac Cardiovasc Surg 2012.
33. Szabo G, Romics L Jr, Frendl G. Liver in sepsis and systemic inflammatory response syndrome. Clin Liver Dis 2002; 6:1045-1066. (Pubitemid 36026462)
34. Portincasa P, Grattagliano I, Testini M, et al. Parallel intestinal and liver injury during early cholestasis in the rat: modulation by bile salts and antioxidants. Free Radic Biol Med 2007; 42:1381-1391. (Pubitemid 46476849)
35. Aouad K, Calmus Y, Nordlinger B, et al. Immunosuppressive effects of endotoxins and bile acids in vivo in the rat. Eur J Clin Invest 1996; 26:45-48. (Pubitemid 26046787)
36. Ockenga J, Valentini L, Schuetz T, et al. Plasma bile acids are associated with energy expenditure and thyroid function in humans. J Clin Endocrinol Metab 2012; 97:535-542.
37. Uslu A, Tasli FA, Nart A, et al. Human kidney histopathology in acute obstructive jaundice: a prospective study. Eur J Gastroenterol Hepatol 2010; 22:1458-1465.
38. Peralta C, Perales JC, Bartrons R, et al. The combination of ischemic preconditioning and liver Bcl-2 overexpression is a suitable strategy to prevent liver and lung damage after hepatic ischemia-reperfusion. Am J Pathol 2002; 160:2111-2122. (Pubitemid 34663403)
39. Nielsen VG, Tan S, Baird MS, et al. Xanthine oxidase mediates myocardial injury after hepatoenteric ischemia-reperfusion. Crit Care Med 1997; 25:1044-1050. (Pubitemid 27264251)
40. Taura P, Fuster J, Mercadal J, et al. The use of beta-adrenergic drugs improves hepatic oxygen metabolism in cirrhotic patients undergoing liver resection. J Hepatol 2010; 52:340-347.
41. Acharya SK, Bhatia V, Sreenivas V, et al. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009; 136:2159-2168.
42. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41:1179-1197. (Pubitemid 40593928)
43. Geier A, Fickert P, Trauner M. Mechanism of disease: mechanism and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol 2006; 3:574-585. (Pubitemid 44489590)
44. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10:R108.
45. Schmidt LE, Sorensen VR, Svendsen LB, et al.Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001; 7:1034-1039. (Pubitemid 34023990)
46. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003; 9:290-297. (Pubitemid 36322332)